Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Adv Healthc Mater. 2020 Jul 21;10(5):e2000690. doi: 10.1002/adhm.202000690

Figure 7.

Figure 7.

Matrix metallopeptidase-2 (MMP-2)-activated multimodal imaging. a) MMP-2 mediated cleavage of T-MAN enhanced the FL intensity. In vivo imaging with b) activatable FL imaging could delineate the subcutaneous tumors, while c) MR imaging provided enhanced soft-tissue contrast. d) FL and e) MR imaging with T-MAN could also visualize tumors for surgical resection in an orthotopic tumor model. In (d), bioluminescence (BL) from the orthotopic tumor cells confirmed T-MAN uptake in the tumor. In (b) and (c), I–IV represent the activatable, blocking control, nonresponsive control, and activatable and MMP-2 inhibitor groups, respectively. Reproduced with permission.[59] Copyright 2019, American Chemical Society.